Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
Investing.com - Xtant Medical (NYSE: XTNT) reported first quarter EPS of $0.2791, $0.29 better than the analyst estimate of $-0.0100. Revenue for the quarter came in at $32.9M versus the consensus estimate of $31.58M.
Guidance
Xtant Medical sees FY 2025 revenue of $127.0000M-$131.0000M versus the analyst consensus of $128.3000M.
Xtant Medical’s stock price closed at $0.52. It is down -12.9000% in the last 3 months and down -36.3800% in the last 12 months.
Xtant Medical saw 1 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Xtant Medical’s stock price’s past reactions to earnings here.
According to InvestingPro, Xtant Medical’s Financial Health score is "good performance".
Check out Xtant Medical’s recent earnings performance, and Xtant Medical’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar